Smith Giri

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova et al. · Journal of Clinical Oncology · 2021 · 255 citations

Medicine, Hematology, Pharmacotherapy +17

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova et al. · The Lancet Haematology · 2023 · 150 citations · Full text

Medicine, Internal Medicine, Oncology +12

Low Birth Weight at Term and Its Determinants in a Tertiary Hospital of Nepal: A Case-Control Study

Sudesh Raj Sharma, Smith Giri, Utsav Timalsina et al. · PLoS ONE · 2015 · 133 citations · Full text

Public Health, Child Health, Maternal Health +17

Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States

Amer M. Zeidan, Rong Wang, Xiaoyi Wang et al. · Blood Advances · 2020 · 89 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Early mortality and overall survival of acute myeloid leukemia based on facility type

Vijaya Raj Bhatt, Valerie Shostrom, Smith Giri et al. · American Journal of Hematology · 2017 · 83 citations · Full text

Medicine, Oncology, Chemotherapy +13